US National Institute of Allergy and Infectious Diseases announced on the 18th that they would carry out large-scale clinical trials in South Africa later this year to test the effectiveness of an AIDS vaccine combination which is widely considered promising.
Such a combination of AIDS vaccine is made of a vaccine which stimulates the immune system and a vaccine which enhances immune response. A landmark trial in 2009 in Thailand shows that it can reduce the risk of human infection by about 31%. After improvements, scientists in South Africa launched a small and preliminary study, and the results show that it has security and can trigger a strong immune response.
US National Institute of Allergy and Infectious Diseases said in a statement that if all goes well, this large-scale trial will be carried in South Africa in November 15 sites. They would recruit 5400 healthy adults with higher risk of infection aging between 18 to 35 years. Each participant will be vaccinated five times a year and randomly assigned to the vaccine or a placebo. Test results are expected to be released in the second half of 2020.
Director Anthony Fauci of the Institute said, "This will be the first time that the scientific community carries out large-scale clinical trials of AIDS vaccine in seven years. Safe and effective vaccine will continue to help to end the AIDS epidemic. AIDS in southern Africa is more serious than other places in the world. Thus they need AIDS vaccine particularly."
AIDS has been found for 30 years, and to develop an effective AIDS vaccine is always a tireless pursuit of the goal of the scientific community, but progress had been slow. To carry out such a combination vaccine study in South Africa is placed high hopes for the scientific community.
没有评论:
发表评论